Table 5.
Strategies for monitoring patients with classic galactosemia during Puberty
| COUNTRY (City) |
CLINICAL PARAMETERS TO FOLLOW | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ENDOCRINE DEVELOPMENT |
SCHOOL PERFORMANCE |
BEHAVIOR SOCIAL SKILLS |
BONE DENSITY |
OPHTALAMOLOGIC EVALUATION |
OVARIAN FUNCTION |
NEUROLOGICAL DEVELOPMENT |
BLOOD/URINE PARAMETERS |
LIVER FUNCTION |
GROWTH AND DEVELOPMENT |
|
| UK (Manchester) |
|
|
|
|
|
Annual FSH, LH and estradiol |
||||
| Netherlands (Amsterdam) |
|
|
|
|
in case of residual cataract |
|
Includes speech evaluation |
Hormone levels at 10-12 years old |
|
|
| Mexico (Mexico City) |
|
N/A | Total galactose |
|
|
|||||
| Croatia (Zagreb) |
|
|
|
|
|
Liver function tests |
|
|
||
| Italy (Padova) |
|
|
|
|
|
|
Gai-1P, total galactose, slalotransferrin profile, FSH, LH |
|||
| Spain (Santiago de Compostela) |
NO INFORMATION | |||||||||
| Germany (DQsseldorf) |
|
|
|
|
Gal-1P, urine galactitol, calcium creatinine ratio, annual FSH, LH, estradiol from age 9 |
|
||||
| South Africa (Cape Town) |
NO INFORMATION | |||||||||
| United States (Cincinnati) |
|
|
|
|
FSH/LH | |||||
| United States (Salt Lake City) |
|
|
|
FSH, LH, estradiol from age 10-11 |
||||||
| United States (Boston) |
|
|
|
|
|
Gal1P, galactitol, FSH, LH,estradiol, 25-OH VitD |
|
|||
| Argentina (Buenos Aires) |
NO INFORMATION | |||||||||
| Philippines (Manila) |
|
|
|
|
|
|
|
Total galactose, FSH, LH and estradiol if no pubertal signs by age 15 |
|
|